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Abstract
The use of ventricular assist devices has expanded significantly since their approval by the Food and Drug
Administration in the United States in 1994. In addition to this, the prevalence of heart failure continues to increase.
We aim to provide an overview of perioperative considerations and management of these patients for non-cardiac
surgery. We performed a Medline search for the words “ventricular assist device,” “Heartmate” and “HeartWare” to
gain an overview of the literature surrounding these devices, and chose studies with relevance to the stated aims
of this review. Patients with ventricular assist devices are presenting more frequently for surgery not related to their
cardiac pathology. As the mechanically supported population grows, general anesthesiologists will be faced with
managing these patients, possibly outside of the tertiary care setting. The unique challenges of this patient
population can best be addressed by a thorough understanding of ventricular assist device physiology and a
multidisciplinary approach to care.
Keywords: Heartware, Heartmate, Ventricular assist device, Perioperative management
Background
Since the approval of ventricular assist devices (VADs)
by the Food and Drug Administration (FDA) in the
United States in 1994, their indications and prevalence have
continued to expand [1]. Thanks to advances in cardiovas-
cular care allowing for survivability of cardiovascular in-
sults, the prevalence of heart failure continues to increase
with an estimated 670,000 new cases each year, $34 billion
in associated healthcare costs annually, and a total
population of 5.8 million heart failure patients in the
United States [2, 3]. Initially, these support devices were
approved to bridge end-stage heart failure patients await-
ing transplant, termed “bridge-to-transplant”. However,
approximately 30,000 patients are listed for heart trans-
plantation per year but only 3500 are performed [4]. The
findings of improved hemodynamics, end-organ function,
exercise tolerance, and overall improvement in quality of
life thanks to left ventricular assist device (LVAD) therapy
led to device implantation for non-transplant candidates
as well, termed “destination therapy”. The REMATCH
and INTrEPID trials demonstrated a significant reduction
in all-cause mortality and nearly tripled 2-year survival
comparing LVAD implantation to optimal medical therapy
[5, 6]. LVAD therapy has even been shown to transition
NYHA (New York Heart Association) Class IV patients to
Class I or II [7]. These patients are able to be discharged
from the hospital and, thanks to their improved survivor-
ship, may present for non-cardiac surgical procedures
unrelated to their heart failure pathology. Prior studies have
demonstrated that 23–27 % of LVAD patients undergo
non-cardiac surgery [1]. As the mechanically supported
population grows, general anesthesiologists will be faced
with managing these patients more frequently, possibly
outside of the high-level tertiary care setting [7, 8]. The
authors intend to provide an overview of currently available
LVAD technology as well as perioperative considerations
and management of these patients for non-cardiac surgery.
Review
Current ventricular assist devices
Since their first use in the early 1990s, VADs have devel-
oped and undergone multiple evolutions resulting in the
devices currently in use. First-generation devices attempted
to assist the failing ventricle by assuming its pump function.
These pumps were either pneumatically or electrically
driven and operated in a fill-to-empty mechanism, which
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produced pulsatile flow in an asynchronous fashion with
the native ventricle [9]. These devices were noisy, large
and required the pump chambers be extracorporeal or
implanted into the abdomen with larger percutaneous
drivelines [10]. These complex devices had a high
incidence of complications including mechanical fail-
ure, infection and thromboembolic events [11].
Second generation devices abandoned efforts to replace
the function of the ventricle and instead unload volume
from the failing ventricle in a continuous, nonpulsatile
fashion. An inflow cannula is placed in either the left
atrium or, more commonly, the apex of the left ventricle
(LV) and blood is pumped via a rotating impeller in an
axial or centrifugal fashion to the ascending aorta [11, 12].
These devices are vastly smaller, totally implantable gener-
ally into the pericardial space, silent, dependable, and re-
quire less anticoagulation than most of the prior
generation devices thanks to their valveless, continuous-
flow systems [10–13]. The newest third-generation
devices employ the same continuous-flow mechanisms,
but make small improvements, such as hydrostatic or
magnetic bearings which minimize shear stress and the
incidence of thrombus formation [10]. Though multiple
second and third generation devices are in development
and undergoing investigative trials, there are currently two
devices approved by the FDA for use in adults [14, 15].
The HeartMate II® (Thoratec Corp., Pleasanton, CA,
USA) (Figs. 1, 2, 3) is a second-generation, axial flow,
rotary pump approved for both bridge-to-transplant
and destination therapy in the US, and is currently
implanted in over 7000 patients [10]. Its speed is fixed
and can only be adjusted by medical professionals. The
external display of the device shows speed (RPM),
power (W), pulsatility index, and flow (l/min) which is
an estimated value based on power utilization. Typical
pump speed ranges between 6000 and 15,000 RPM with
pump power ranging from 6.8 to 15.5 W. Pulsatility index
(PI) is a dimensionless value with a usual range of 3–4. The
variation in pump flow (Q) is used to derive the PI: 10 ×
(Qmax – Qmin)/Qavg. These values can be monitored on an
external display, which can be useful clinically (i.e., flow as
a surrogate for cardiac output) [10, 16].
The HVAD™ (HeartWare Inc., Miami Lakes, FL, USA)
(Figs. 4 and 5) is a third-generation centrifugal pump
recently approved by the FDA for bridge-to-transplant in
November of 2012. The most notable differences between
the HeartMate II and the HVAD™ are its smaller size,
centrifugal as opposed to axial pumping mechanism, and
its lack of mechanical bearings. It utilizes hydrodynamic
forces to suspend the impeller in an attempt to reduce the
risk of mechanical failure, prolong pump life, and decrease
the risk of thrombus formation [17]. Studies, however,
have shown similar survival rates but increased incidence
of stroke and gastrointestinal bleeding in patients with
HVAD when compared to HeartMate II, though some
reports have also shown similar rates of adverse events
[2, 13]. Similar to the HeartMate II, the control screen
displays pump speed, power, and an estimated pump flow,
as well as graphical displays of pulsatility. Pump speed
ranges between 1800 and 4000 RPMs and power ranges
Fig. 1 Schematic of Heartmate 2, with battery. Legend – The power
supply for the Heartmate 2 is worn externally, connecting to the
device via the system controller
Fig. 2 Cross section of Heartmate 2. Legend – The internal workings
of the Heartmate 2 are shown in this schematic. The rotary pump is
shown, as well attachments to the inflow and outflow tract
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from 2.5 to 8.5 W [18]. The lower speed range of the
HVAD™ is hypothesized to have less extreme hemodynamic
effects and decreases the risk of creating sufficient negative
pressure to cause “suction events” when a ventricular wall
is drawn toward the inflow cannula causing complete or
partial obstruction [13]. Overall, despite these differences,
both the HeartMate II and HVAD™ can be managed with
similar clinical principles.
LVAD Physiology
The physiologic changes associated with heart failure
are complex and systemic. These patients clearly
have reduced stroke volume and cardiac output
associated with slow circulation times and decreased
end-organ hypoperfusion. Compensation occurs via
neurohormonal activation—high circulating catechol
amines, natriuretic peptides, endothelin, and activation
of the renin-angiotensin-aldosterone system—which
results in ventricular remodeling. Hence, the mainstay
of treatment is neurohormonal blockade [12]. The
long-term effects of this malperfused and overly com-
pensated state frequently result in hepatic, renal, or
pulmonary insufficiency [19]. Continuous-flow LVAD
implantation results in an off-loading of volume from
the ventricle. This decompression results in decreased left
ventricular work, reduces myocardial damage, improves
chamber compliance, and favors “reverse remodeling” by
improving left ventricular geometry [9]. The device im-
proves arterial blood pressure and microcirculation, des-
pite its non-pulsatile nature, which enhances end-organ
perfusion and restores function [10]. These improved
hemodynamics are also evidenced by reductions in the
aforementioned neurohormonal response measured in the
plasma [9]. Decompression of the LV also reduces
pulmonary pressures and transpulmonary gradient, which
is a factor that improves transplant candidacy [10]. Overall,
LVAD implantation enhances end-organ and myocardial
function, exercise tolerance, and overall quality of life [5, 9].
The device itself also depends upon several physiologic
variables. The output of second- and third-generation
devices is directly related to pump speed and inversely re-
lated to the pressure gradient across the pump [10, 16, 20].
These devices have continuously rotating impellers which
continue to pump at a fixed speed regardless of their
environment. For this reason, volume status and right
ventricular (RV) function have a significant impact on
LVAD flow and, therefore, cardiac output [16]. Despite a
supported LV, patients may have coexisting right ventricu-
lar failure which may require inotropic support or pulmon-
ary vasodilation to enhance RV stroke volume [19].
Afterload also has a large impact on LVAD function, as it
directly impedes LVAD flow. Increases in systemic vascular
resistance will have adverse effects on device output [16].
Pulsatility may be variable as the physiologic environment
changes and is inversely related to how well the LVAD is
Fig. 3 Chest X-ray showing radiographic appearance of Heartmate 2.
Legend – This shows the radiographic appearance of the inflow and
outflow tracts of the Heartmate 2 device. Note the power and control
cable attached to the pump unit
Fig. 4 Heartware Device. Legend – HeartWare device implants
directly into apex of left ventricle. Blood from LV passes through the
device and into the left ventricle outflow tract
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off-loading volume from the native ventricle. If pulsatility
increases significantly, it may be an indication of volume
overload to the LV [10]. Overall, the goal is to maintain
flow by ensuring adequate preload and RV contractility,
while managing systemic vascular resistance to allow for
optimal pump function.
Another important physiologic consideration after
LVAD implantation is the coagulopathy associated with
shear stress and nonpulsatile flow. Evidence suggests an
acquired von-Willebrand Syndrome exists where a
decreased amount of circulating high-molecular-weight
von-Willebrand multimers are found, similar to that of se-
vere aortic stenosis [10, 13, 21, 22]. Likewise, a coinciding
platelet dysfunction occurs, which is more significant in
nonpulsatile pumps than in their pulsatile predecessors
[10]. These qualitative factors place patients at an in-
creased risk of nonsurgical bleeding as evidenced by an in-
creased incidence of gastrointestinal bleeding [20]. This
risk is also increased due to the finding of arteriovenous
malformations in the gut due to the nonpulsatile flow and
decreased capillary pressure [13]. Thanks to this acquired
coagulopathy, only mild levels of anticoagulation are re-
quired after implantation of second- and third-generation
devices. Likewise, withholding anticoagulation periopera-
tively has been shown to be safe, which will be discussed
further [1, 20, 23].
Preoperative evaluation
In addition to the standard components of a preopera-
tive assessment, evaluation of a patient with an LVAD
should include a few additional components. When pos-
sible, all LVAD patients undergoing non-cardiac surgery
should have a multidisciplinary team of subspecialists
coordinating their care. This should include not only the
primary surgical and anesthesia teams, but also cardiac
surgery, heart failure cardiologists, and dedicated VAD
personnel [1, 7, 11, 20, 24, 25]. This may involve contact-
ing the nearest tertiary care center for these resources,
since the combined knowledge of these individual parties
may be paramount to the successful care of these patients.
It may also be necessary to contact the VAD manufacturer
for emergency resources [26]. At times, the patient may
also be best served by preoperative medical optimization
guided by heart failure cardiologists [1, 24]. This multifa-
ceted approach ensures optimal care of a complex patient
throughout the perioperative period.
Next, baseline physical exam findings should be
noted, with special concern to organ systems which may
be affected by the baseline heart failure (renal, hepatic,
or pulmonary) or those which may be affected by LVAD
complications, such as a neurologic deficit secondary to
a thromboembolic event. Assessment of laboratory
values with attention to the same organ systems should
be included [8, 26]. Many LVAD patients may also have
implanted defibrillators or pacemakers, so an electro-
cardiogram should be reviewed and the consensus
statement from the American Society of Anesthesiologists
and the Heart Rhythm Society should be followed
[16, 27]. A review of prior echocardiography findings,
particularly transesophageal echocardiography (TEE), may
be useful in order to compare baseline findings with an
intraoperative evaluation, as hemodynamics can change
throughout the procedure [20].
All modern LVAD patients will generally be maintained
on anticoagulation, which will have to be managed
preoperatively. Patients, therefore, will generally not be
candidates for neuraxial anesthesia [8, 16, 26]. Both the
HeartMate II and HVAD patients should have an INR
of 2–3, aspirin 81 mg daily, and may include dipyrid-
amole 75 mg three times daily or clopidogrel 75 mg
daily [18, 28]. Recently, slightly lower INR goals of
1.5–2 have been recommended for the Heartmate II,
and less stringent anticoagulation has recently been
supported [2, 13, 29]. Warfarin should be discontinued at
least 2–5 days preoperatively and patients should receive a
heparin infusion which should be stopped the morning of
the planned procedure [7, 16, 20, 30, 31]. For patients with
a history of heparin-induced thrombocytopenia, both
argatroban and bivalirudin have safely been utilized as well
[32, 33]. As always, the risks of hemorrhage should be
weighed against the risk of thromboembolic events,
Fig. 5 Heartware Device. Legend – The Heartware device implants
directly into the left ventricle. The centrifugal pump design leads to
a more compact device. The impeller is suspended using
hydrodynamic forces to reduce the risk of thrombotic events
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though the risk of bleeding is generally higher than the
risk of thrombus with these devices, thanks to the
aforementioned changes in platelet and von-Willebrand
factor function [20, 22, 34]. In a case series of 20 patients
with second- and third-generation devices, anticoagula-
tion was transitioned to a heparin infusion (as above)
without any thrombotic complications. They conclude
that, if there are concerns for hemorrhage before or after
surgery, anticoagulation can be safely held [1, 23].
Other case series have shown intraoperative erythrocyte
transfusion requirements in 15–90 % of LVAD patients
undergoing non-cardiac surgery, though the higher
transfusion rates were found in a small series of 11 patients
[1, 16, 34]. Overall, providers should transition anticoagula-
tion appropriately, withhold it entirely if there are concerns
for hemorrhage, and be prepared for transfusion when
indicated. Patients awaiting transplantation should receive
leukoreduced and irradiated blood products, though indi-
cations for transfusion are unchanged from patients with-
out devices [35].
Hemodynamic monitoring
Intraoperative monitoring of LVAD patients presents
unique challenges due to their nonpulsatile nature.
Standard ASA monitors, such as pulse oximetry and
noninvasive blood pressure monitoring, rely on pulsatility
and oscillations, respectively. Cerebral tissue oxygenation
(SctO2) measurements have been used successfully as a
surrogate for pulse oximetry in these patients [11, 16, 26].
The monitor should be placed pre-induction while the
patient is awake, and efforts should be directed at
maintaining these baseline values throughout the procedure
[20]. Serial arterial blood gas measurements are another
alternative, though this approach is invasive and lacks the
advantage of real-time data that cerebral oximetry provides
[16]. Given concerns for infection, invasive monitoring
should be avoided whenever possible. Pulmonary artery
catheters are generally not required. Pump flow (an
indicator of cardiac output) is displayed on the LVAD
screen; therefore, pulmonary artery (PA) catheters provide
little additional information. The exception to this may be
patients with significant pulmonary hypertension at risk for
right ventricular failure [8, 16, 20, 30, 34]. Noninvasive
blood pressure devices may detect mean arterial pressure,
but an arterial line should be placed (likely requiring ultra-
sound guidance) if hemodynamic fluctuations are expected
[7, 8, 11, 16, 20, 24, 26]. In published case series, the use of
arterial lines varies widely from 0 to 100 %, though they are
generally indicated for most patients undergoing general
anesthesia [1]. Central venous catheters may also be
indicated if significant fluid shifts are expected [7, 8,
11, 20]. The monitor of choice, however, is the use of
transesophageal echocardiography [8, 20, 30]. TEE al-
lows full evaluation of important elements that effect
LVAD function, such as volume status, RV function, in-
flow cannula position, and LV decompression [16, 26].
One final monitor to consider is the use of processed
EEG, given the fact that hypertension and tachycardia
may not be a reliable indicator of inadequate anesthetic
depth in LVAD patients [16].
Intraoperative management
After preoperative optimization and coordination of a
multidisciplinary team, when patient condition permits,
the patient can be taken to the operating room. Patients
should be transported to the operating room in coordin-
ation with VAD personnel who have knowledge of VAD
intricacies, such as connecting the portable power supply,
control console and changing VAD settings if necessary.
Once in the operating room, the device should be attached
to a secure power supply for the duration of the procedure
[1, 7–9, 11, 20, 30]. Hemodynamic monitors should be
placed as discussed above Table 1. Additionally, external
defibrillator pads should be applied [16, 26]. Bipolar cautery
should be utilized whenever possible, and the grounding
pad should be placed away from the device to limit
electromagnetic interference [4, 7–9]. Induction of
anesthesia, when appropriate, may then proceed.
The presence of an LVAD does not preclude the use of
anesthetic drugs or techniques that would otherwise be
acceptable for these patients. Standard induction agents
and balanced anesthetic techniques have been used
safely [7, 8, 11, 16, 20, 30]. Generally, however, LVAD
patients would not be candidates for neuraxial
anesthesia given their anticoagulation status. Standard
laryngoscopy and intubation is acceptable for patients
with second- and third-generation devices implanted in
the pericardial space; however, patients with first-
generation devices implanted in the peritoneal space
should be considered an aspiration risk and induced
using a rapid sequence technique [8, 16, 20, 26, 30].
Goals of care for LVAD patients undergoing non-
cardiac surgery should be directed at maintaining
forward flow and adequate perfusion. Three main
factors that affect LVAD flow are preload, RV function,
and afterload. First, optimizing preload includes ensur-
ing adequate volume status without overloading the
right ventricle [7, 9, 11]. Acute volume overload may
precipitate isolated RV failure in 20–30 % of LVAD pa-
tients [30]. However, a careful assessment of volume
status should be completed as certain patients may
benefit from preoperative volume loading, depending
on the clinical scenario [7]. Maintaining spontaneous
ventilation, when possible, may augment venous return
as well [8, 16, 30]. When positive pressure ventilation is
necessary, adequate oxygenation and ventilation should
be balanced with minimizing intrathoracic pressure,
which adversely affects preload [16].
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The right ventricle is the primary means of LVAD fill-
ing; therefore, maintaining RV function is imperative
[26]. Negative inotropes should be used with caution
[7]. Any decreases in oxygenation, ventilation or high
levels of positive end-expiratory pressure will increase
pulmonary vascular resistance and thus adversely
affect RV function [7, 9, 11, 26]. RV strain will then
worsen hypoxia and respiratory acidosis and further
exacerbate RV failure and decrease VAD flow. With
appropriate safeguards, even one-lung ventilation has
been performed safely in an LVAD-dependent patient
without changes in oxygenation, ventilation, or
hemodynamics [16]. Finally, care should be taken to man-
age systemic vascular resistance as afterload directly im-
pedes LVAD flow. Marked increases in systemic vascular
resistance should be avoided [11]. Sympathetic discharge
from laryngoscopy or surgical stimulation may cause an
overt rise in afterload; for this reason, adequate anesthetic
depth should be ensured to avoid any abrupt change in
systemic vascular resistance [7, 9]. Not only does decreased
VAD flow impair peripheral perfusion, but it may also pro-
mote stasis of blood in the device and increase the risk of
thromboembolic events [7, 11].
Keeping in mind the LVAD’s preload dependence and
afterload sensitivity is key to managing changes in
hemodynamics [7, 20, 34]. Though displayed VAD flow
is an estimate based on power utilization, these values
should be trended carefully throughout the procedure
[16]. Changes in VAD flow should be combined with
other available information, such as operative conditions,
arterial pressure, central venous pressure, and TEE
findings to diagnose the etiology of decreased flow.
Generally, decreases in pump flow should first be treated
with a fluid challenge. Hypovolemia should be avoided
and intraoperative losses should be replaced aggres-
sively [11, 26]. Second line treatment should include
inotropic support for the right ventricle [7, 20]. For
example, decreased LVAD flow and a continuously
rising central venous pressure may be indicative of
RV failure. In this case, appropriate management would
include supporting the right ventricle with inotropes and
pulmonary vasodilators, as opposed to a fluid bolus
[7, 9, 11, 16, 26]. If, however, hypotension is accom-
panied by increases in LVAD flow, this may be due to
decreased systemic vascular resistance. In this case,
vasopressors should be titrated carefully to balance
adequate perfusion pressure with forward flow [16].
Low-dose vasopressin (<2.4 U/h) may be the vasopressor
of choice due to its minimal effect on pulmonary vascular
resistance [11, 26]. Cerebral tissue oxygenation should also
be monitored carefully throughout the procedure. Signifi-
cant decreases from baseline should first be treated with
increased inspired oxygen. If the decreased SctO2 is
accompanied by decreases in LVAD flow, it should be
treated as described above with first a fluid challenge, then
inotropic support [20].
Managing arrhythmia may present a unique challenge
in LVAD-dependent patients. Many patients may have
implanted defibrillators or pacemakers which may re-
quire reprogramming prior to the procedure [16, 27].
External defibrillator pads should be in place [16, 26].
Patients should be kept in normal sinus rhythm when
possible. Arrhythmia may impair the unassisted ventricle
and decrease inflow to the LVAD [20]. Standard Advanced
Cardiovascular Life Support Guidelines should be
followed; however, external chest compressions should
be avoided during cardiac arrest [26, 36]. Compressions
risk cannula dislodgement, which may result in life-
threatening hemorrhage [7, 8, 16].
Intraoperative events that affect preload and afterload
should be completed cautiously. Position changes should
be performed gradually and extremes in position should
be avoided. Preoperative volume loading has been shown
to stabilize hemodynamics when positions are required
that decrease preload, such as lateral decubitus or re-
verse Trendelenburg [7, 8, 16, 26, 30]. Likewise, steep
Trendelenburg may increase venous return, risking RV
strain. Peritoneal insufflation for laparoscopic surgery also
increases afterload and has detrimental effects on preload.
Insufflation should utilize minimum pressures and be
Table 1 Perioperative approach to LVAD patients undergoing
non-cardiac surgery
• Preoperative
oMultidisciplinary team identified (primary surgical and anesthesia
teams, cardiac surgery, heart failure cardiologist, VAD personnel)
o Preoperative medical optimization when possible or necessary
o Physical examination focused on the sequelae of heart failure
o Baseline EKG, echocardiogram, and laboratory values
oManage pacemaker/AICD settings when indicated
o Hold, bridge, or reverse anticoagulation when indicated
• Intraoperative
o Standard ASA monitors
o Cerebral tissue oxygenation, processed EEG, arterial line with
ultrasound guidance, central venous catheter if fluid shifts are
expected, PA catheter only if severe pulmonary hypertension, TEE
available
oMonitor VAD control console
o External defibrillator pads in place
oOptimize preload, support RV function, avoid increased in afterload
o Gradual peritoneal insufflations and position changes
• Postoperative
o Standard PACU care unless ICU is otherwise indicated
o Extubation criteria are unchanged
o Avoid hypoventilation, optimize oxygenation
o Resume heparin infusion when post-op bleeding risk is acceptable
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increased in a gradual, step-wise fashion [7, 16, 20, 26].
However, standard insufflation pressures have been uti-
lized safely for laparoscopic surgery [7, 20, 37].
Managing device complications may present a
challenge that requires a multidisciplinary team to
diagnose and treat [38]. Motor failure is an extremely
rare complication that presents with symptoms of
worsening heart failure, increased pulsatility, and de-
creased arterial pressure. Patients require urgent consult-
ation with cardiac surgery for possible replacement. A
more common device issue is obstruction of the inflow
or outflow cannula. This may be caused by thrombus, a
kinked cannula, or a “suction event”. Obstruction pre-
sents as decreased pump flow, decreased arterial pres-
sure, and increases or decreases in pump power. TEE can
be extremely valuable in diagnosing the cause of obstruc-
tion. A suction event occurs when the LV is under filled
due to hypovolemia or RV failure. This causes the intra-
ventricular septum or free wall of the ventricle to col-
lapse against and obstruct the inflow cannula. This
presents as with the signs of obstruction and may include
tachyarrhythmia as well. If this is suspected, it should be
aggressively treated with a fluid challenge. Decreasing the
pump speed temporarily may also allow for improved LV
filling, though this requires close coordination with the
VAD personnel [34].
Postoperative management
In general, the postoperative care of LVAD-dependent
patients undergoing non-cardiac surgery is largely un-
eventful. Patients should be extubated when they meet
standard criteria [20, 24, 30]. Special care should be
taken to ensure acceptable oxygenation and ventilation
to avoid changes in pulmonary vascular resistance [16].
Most patients can be recovered in the standard post-
anesthesia care unit, unless intensive care is otherwise
indicated [1]. A major concern in the postoperative course
will be the resumption of anticoagulation. Patients who
are both anticoagulated and on antiplatelet therapy are at
risk for hemorrhagic postoperative complications [34].
However, heparin infusion should be resumed when the
risk of postoperative bleeding is acceptable [4]. Case series
have reported resuming heparin infusions immediately
following surgery or up to 26 h later [34, 37]. There are
also reports of foregoing heparin infusion entirely and
transitioning directly to oral anticoagulants without
increased risk of thromboembolism [23]. Oral anticoa-
gulation can be resumed when bleeding from surgical
drains ceases, though the heparin infusion should be
continued until the patient reaches their goal INR
[24, 34]. Aspirin management varies widely in previously
reported cases, though most report the resumption of
aspirin one week postoperatively [34]. Again, second- and
third-generation devices have a low thromboembolic risk
so the risk of perioperative hemorrhage may be greater
than the risk of thrombus formation; therefore, adequate
hemostasis should be ensured prior to the resumption of
full anticoagulation [20, 23].
Conclusions
There is an increasing frequency of LVAD-dependent
patients presenting for non-cardiac surgery. These
trends will likely increase due to advances in cardiac
care and the consequent increase in life expectancy
and prevalence of end-stage cardiac disease. The gen-
eral anesthesiologist needs to be prepared to evaluate
these patients and mitigate cardiac risk in the
perioperative period. The unique challenges of this
patient population can best be addressed by a thorough
understanding of LVAD physiology and a multidisciplinary
approach to care.
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